REFERENCES
- Kobayashi H. Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. Am J Med 1987; 82 ( 4A): 169-73.
- Hoogkamp KJ, Klein SJ. Ciprofloxacin in acute exacer-bations of chronic bronchitis. J Antimicrob Chemother 1986; 18 (3): 407–13.
- Grassi C, Catena E et al. Pefloxacin in lower respiratory tract infections. J Antimicrob Chemother 1990; 26 ( B): 103-10.
- Jorgensen JH, Doern GV, Thornsberry C et al. Susceptibility of multiply resistant Haemophilus influenzae to newer antimicrobial agents. Diagn Microbiol Infect Dis 1988; 9 (1): 27-32.
- Hoogkamp KJ, Klein SJ. Treatment of acute exacerba-tions of chronic bronchitis with ciprofloxacin. Pharm Weekbl Sci 1987; 11 (9): 60–3.
- Barriere SL, Hindler JA. Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease. Ann Pharmacother 1993; 27 (3): 309–10.
- Vellend H. Role of fluoroquinolones in lower respirato-ry tract infections. Clin Invest Med 1989; 12 (1): 39–43.
- Davies BI, Maesen FP, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 1986; 5 (2): 226–31.
- Petitjean O, Pangon B, Brion N et al. Pharmacokinetics and bactericidal activities of one 800-mg dose versus two 400-mg doses of intravenously administered pefloxacin in healthy volunteers. Antimicrob Agents Chemother 1993; 37 (4): 737-40.
- Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microb Infect Dis 1991; 10 (4): 267–74.
- Frydman AM, Le RY, Lefebvre MA, Djebbar F, Fourtillan JB, Gaillot J. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother 1986; 17 ( B): 65-79.
- Bergeron MG. The pharmacokinetics and tissue pene-tration of the fluoroquinolones. Clin Invest Med 1989; 12 (1): 20–7.
- Bergan T, Thorsteinsson SB, Solberg R, Bjomskau L, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med 1987; 82 ( 4A): 97-102
- Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992; 36 (5): 993–6.
- Bomer K, Hoffken G, Lode H et al. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intra-venous administration. Eur J Clin Microb 1986; 5 (2): 179–86.
- Arpi M, Gahrn HB, Sogaard P, Bentzon MW. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates. Acta Pathol Microb Immunol Scand 1987; 95 (2): 141–6.
- Gonzales JP, Henwood JM. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and thera-peutic use. Drugs 1989; 37 (5): 628–68.
- Kees F, Naber KG, Meyer GP, Grobecker H. Pharmacokinetics of ciprofloxacin in elderly patients. Arzneimittelforschung 1989; 39 (4): 523–7.
- King A, Phillips I. The comparative in vitro activity of pefloxacin. J Antimicrob Chemother 1989; 1 (1): 10–7.
- Bergan T. Pharmacokinetics of ciprofloxacin with refer-ence to other fluorinated quinolones. J Cemother 1986; 17 ( B): 1-10.
- Lode H. Pharmacokinetics and clinical results of per-enterally administered new quinolones in humans. Rev Infect Dis 1989; 11 (5): 996–1004.
- Webberley JM, Andrews JM, Ashby JP, McLeod A, Wise R. Pharmacokinetics and tissue penetration of orally administered pefloxacin. Eur J Clin Microbiol 1987; 6 (5): 521–4.